Sivia Capital Partners LLC Boosts Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sivia Capital Partners LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 634 shares of the medical research company’s stock after buying an additional 140 shares during the period. Sivia Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $368,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. WCM Investment Management LLC increased its position in Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after purchasing an additional 2,928 shares during the period. Summa Corp. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $418,000. Phoenix Holdings Ltd. boosted its holdings in shares of Thermo Fisher Scientific by 21.4% in the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after buying an additional 1,654 shares in the last quarter. S. R. Schill & Associates boosted its holdings in shares of Thermo Fisher Scientific by 106.3% in the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after buying an additional 792 shares in the last quarter. Finally, Tsfg LLC boosted its holdings in shares of Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after buying an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,000 shares of company stock valued at $12,532,780. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $0.36 on Wednesday, hitting $533.57. The company had a trading volume of 468,115 shares, compared to its average volume of 1,540,680. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The company’s fifty day moving average price is $573.89 and its 200-day moving average price is $563.61. The company has a market capitalization of $203.67 billion, a PE ratio of 34.52, a PEG ratio of 2.58 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on TMO shares. JPMorgan Chase & Co. raised their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. The Goldman Sachs Group lifted their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Barclays decreased their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $606.47.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.